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Summary 
Serum inhibin and FSH and FSH beta subunit mRNA levels were 
measured at 3h intervals throughout the 4 day estrous cycle in female rats and 
hourly between 1000 and 2400 h of proestrus. On proestrus, serum inhibin 
concentrations fell during the late morning-early afternoon, then increased 
transiently during the late afternoon gonadotropin surges. Inhibin levels 
decreased during the late evening of proestrus, coincident with the FSH surge- 
related rise in FSH beta mRNA levels. Serum inhibin remained relatively stable 
during estrus and early metestrus, but rose during the late evening of metestrus 
and remained elevated until early diestrus. FSH beta mRNA levels were 
elevated on late estrus and early metestrus and declined during the evening of 
metestrus as serum inhibin levels increased. These data show that 
concentrations of serum inhibin change during the estrous cycle and that a 
general inverse relationship exists between serum inhibin and FSH levels and 
FSH beta mRNA concena:ations in the pituitary. This suggests that inhibin may 
inhibit FSH beta gene expression and FSH secretion during the 4 day cycle in 
female rats. 
The pattern of gonadotropin secretion during the 4 day rat estrous cycle has previously 
been characterized (1-4). On proestrus, a preovulatory surge of luteinizing hormone (LH) 
occurs during the late afternoon. Follicle stimulating hormone (FSH) also expresses a surge on 
proestrus, but this has a biphasic nature and evidence suggests that it is controlled by different 
mechanisms. Prior work has shown that the first phase of FSH release (as well as LH) is 
stimulated by an increase in pulsatlle secretion of the hypothalamic peptide gonadotropin- 
releasing hormone (GnRH) (5,6). The secondary FSH surge appears to be regulated by 
ovarian inhibin (7,8). Inhibin is a glycoprotein composed of 2 subunits, alpha and beta (9). 
Inhibin has been shown to suppress FSH secretion (10-12) and FSH beta gene expression (12- 
14) by a direct action on the gonadotroph cell. 
We recently characterized the changes in pituitary FSH beta mRNA during the rat estrous 
cycle to increase our understanding of the physiological relationship between FSH secretory 
activity and gene expression (15). Serum samples collected in that study were used to measure 
serum inhibin concentrations in order to establish the relationships between serum inhibin and 
FSH secretion and FSH beta gene expression during the rat estrous cycle. 
0024-3205/90 $3.00 + .00 
Copyright (c) 1990 Pergamon Press plc 
1770 Serum Inhibin During Estrous Cycle Vol. 47, No. 19, 1990 
Materials ~tnd Methods 
Animal Protocol 
Adult female Sprague-Dawtey rats were maintained in controlled lighting (14h of light; 
lights on at 0600h), temperature (23oc) with food and water ad libitum. Vaginal smears were 
taken for 2 weeks and only rats that exhibited at least 2 consecutive 4-day cycles were used. 
Groups of rats (n = 5-11) were decapitated at 3h intervals throughout the cycle and hourly 
between 1000 and 2400h on proestrus. Trunk blood was collected and sera stored at -20°C. 
Anterior pituitaries were removed, snap frozen and stored at -70oc. 
Radioimmunoassavs (RIAs) 
Serum inhibin-levels were measured using an antibody generated against the synthetic rat 
inhibin alpha 1-27 (Tyr 27) peptide fragment as previously described (16). The radioligand and 
standard used in the RIA were the same synthetic peptide. Results were expressed as 
femtomoles/ml (as determined from the 32 KD inhibin molecule). Serum FSH was measured 
by RIA using NIADDK reagents and RP-1 as standard. Serum LH was measured in samples 
on proestrus in order to determine the onset and duration of the proestrus LH surge (using 
NIADDK reagents and RP- 1 as standard). 
mRNA Assessment 
Pituitaries were homogenized under sterile conditions and cytoplasmic RNA extracted with a 
phenol-chloroform-isoamyl alcohol mixture (100:100:1) and quantitated by absorbance at 260 
nm. Nuclear pellets were sonicated and DNA measured by fluorometric assay. RNA samples 
were spotted on nitrocellulose filters (8 ug/spot) in duplicate and hybridized to saturating 
amounts of 32p labeled FSH beta eDNA probe (generously provided by Dr. Richard A. 
Maurer, Univ of Iowa) as described previously (17). FSH beta mRNA levels were expressed 
as femtomoles of cDNA bound/100 ug pituitary DNA as previously reported (15). 
Statistical Analvsis 
Data was analyzed using one way analysis of variance with differences between timepoints 
determined by Duncan's multiple range test. 
Results 
Figure 1C shows serum inhibin concentrations during the rat estrous cycle. Inhibin levels 
remained stable between 0500 h of diestrus through the late morning of proestrus, and 
decreased abruptly between 1100h and 1600h. This decline was followed by a transient rise (2 
fold vs 1300h) in serum inhibin between 1700 and 1900h of proestrus. Serum inhibin declined 
during the late evening of proestrus and remained relatively stable throughout estrus until the 
afternoon of metestrus. During the evening of metestrus, inhibin concentrations rose reaching a 
peak (2 fold increase vs morning of metestrus) at 0200h of diestrus. 
Serum FSH concentrations are shown in Figure 1A. On proestrus, serum FSH began to 
increase at 1800h and peaked at 2000h, coincident with the decline in serum inhibin levels. 
Serum FSH fell on late proestrus - early estrus before the secondary rise at 0500h of estrus. 
Serum FSH remained stable during the later portion of estrous and through metestrus and 
diestrus. The onset and duration of the proestrus LH surge is shown as a horizontal line above 
the serum FSH data in Figure 1A. Serum LH began to rise (>200 ng/mt) between 1600 and 
1700h and remained elevated (> 2100 ng/ml) through 2100h. The peak of the LH surge 
(2440+_1273 ng/ml) was seen at 1800h. FSH beta mRNA concentrations (Fig 1B) rose during 
the FSH surge beginning at 2000h (as serum inhibin levels were declining) and reached a peak 
at 0200h of estrus. A second increase in FSH beta mRNA began at 2300h of estrus and 
continued through the late afternoon of metestrus. FSH beta mRNA declined as serum inhibin 
levels were increasing during the evening of metestrus. 
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Fig. 1 
Serum FSH (A), FSH beta mRNA (B) and serum inhibin (C) concentrations 
during the rat estrous cycle. Mean + SEM for each group (5-11 rats/group) are 
shown. The horizontal line between the arrows above serum FSH values (1A) 
show the timing and duration of  the proestrus LH surge. Panel A: *P < 0.05 vs 
0200-1200h of proestrus. B * P < 0.05 vs all timepoints with mean values less 
than or equal to 0.1 fmol cDNA bound/100 ug pit DNA. Panel C: a p < 0.05 vs 
0200-0800h of  metestrus, b p < 0.05 vs 0500-2000h of diestrus; c p < 0.05 vs 
0200-1000h of  proestrus; d p < 0.05 vs l100-1600h of  proestrus. The FSH 
beta mRNA concentrations have been previously reported (Endocrinology 
123:2149,1988) and are shown here for comparison with the permission of the 
Editor. 
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Discussion 
The present study describes the first characterization of the relationships between serum 
inhibin, FSH secretion and FSH beta gene expression throughout the rat estrous cycle. The 
data agree with recent findings on more limited studies of proestrus (18,19) which showed that 
serum inhibin increases during the evening of proestrus before falling on late proestrus-early 
estrus. The timecourse of this decline in serum inhibin has been shown to parallel observed 
decreases in ovarian inhibin alpha and beta subunit mRNAs (20). Data from other studies 
(21,22) suggest that the decrease in serum inhibin during late proestrus may be regulated by the 
late afternoon gonadotropin surges (either LH, FSH or both) and could be responsible for the 
secondary FSH surge seen during the early morning of estrus. It is of interest that this decrease 
in serum inhibin levels on late proestrus was coincident with the initial FSH surge-related rise in 
FSH beta mRNA concentrations and preceded the FSH beta mRNA peak (0200h of estrus) by 
6h. Serum inhibin also showed a transient decrease during the late morning-early afternoon of 
proestrus. The physiological significance of this decrease is uncertain, but could relate to 
previously observed changes in serum estradiol (E2) concentrations on proestrus. Serum E2 
levels have been shown to decline on the afternoon of proestrus (1,3,18). Other studies (23,24) 
have shown that E2 can stimulate inhibin secretion as well as inhibin subunit gene expression, 
suggesting a possible paracrine regulatory mechanism. It is possible that a fall in ovarian E2 
concentrations might reduce inhibin synthesis and secretion resulting in the transient decrease in 
serum inhibin during the early afternoon of proestrus. 
Beginning on late estrus through the evening of metestrus, FSH beta subunit mRNA levels 
were elevated (approx 2 fold). This was not coupled to a measurable increase in FSH secretion 
similar to previously described increases for pituitary alpha and LH beta subunit mRNAs on 
diestrus (25). The late metestrus decrease in FSH beta mRNA levels was coincident with a rise 
in serum inhibin levels. This increase in serum inhibin during metestrus was also observed in a 
recent study by Hasegawa and colleagues (18). In vitro studies have shown (12,14) that 
inhibin can rapidly and selectively suppress FSH beta gene expression in gonadotroph cells, 
suggesting that the metestrus rise in inhibin secretory activity could be responsible for the 
decrease in FSH beta mRNA levels. 
During the early morning of diestrus, serum inhibin concentrations decreased and remained 
stable for a period of 29h. Approximately one half of the developing follicles recruited as a 
result of the proestrus FSH surge become atretic during metestrus (26). Since the levels of 
inhibin in blood appear to be positively correlated to the number of available follicles (27) the 
decline in serum inhibin on early diestrus might reflect the loss of viable follicles. 
Recent studies provide support for a physiological role of the rise in serum inhibin during 
late metestrus-early diestrus (19). Removal of endogenous inhibin activity by administration of 
inhibin antisera on metestrus and diestrus resulted in a rise in serum FSH, a 2 fold increase in 
ovulation rate and a 2 fold increase in the number of conceptuses in animals that were mated. 
These results suggest that the rise in inhibin between metestrus and diestrus may provide a 
protective effect against overstimulation of the ovary by FSH. 
In summary, alterations in serum inhibin concentrations occur during the rat estrous cycle. 
The data provide support for an inverse relationship between serum inhibin and FSH secretory 
activity and FSH beta gene expression. However, further studies are required to delineate the 
exact physiological interactions between inhibin and FSH synthesis and secretion, and await the 
availability of recombinant inhibin for in vivo studies. 
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